Nasdaq · CIK 0001809519
GDRX GoodRx Holdings, Inc.
B
75 / 100
Material weaknesses
0
Restatements
1
Auditor changes
0
Late filings
0
Quarters with open weakness
0
Remediations
0
Deductions
25
Remediation credit
0
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“concluded that the Company s condensed consolidated financial statements for the fiscal quarter and year-to-date periods ended March 31, 2026 and June 30, 2026 (collectively, the Affected Periods ) should no longer be relied upon due to the understatement of Pharma Direct revenue.”
Filings read
- 8-K · 2026-11-02read
- 10-K · 2026-02-26queued
- 10-K · 2025-02-27queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.